



10,120					1	Nifty	
					1	Open	
10,100					1	High	
1 A. m. M	m,			mh		Low	
10.080	1.	A. M	mar	NI	ALM	Close	
10,000	hul	1 m				% Chg	
10,060	V						
10:00	11:00	12:00	13:00	14:00	15:00		
STOCK INDI	CES	Closi	ing	1D%			

0.00%

+0.83%

0.20

1.39

5.7

3.42

3.34

2.72

2.63

-1.99

-1.4

396.25

416.1

675.8

462.85

285.9

261.55

-2.76 1,202.80

-1.89 2,375.40

-1.57 2,476.45

30,185.2

31283.72

15436.01

7584.50

418.85

430

475

694.2

1,169.65

2,330.50


2,437.60

280.2

257.9

31,219.00

9788.60



Domestic-Corporate-

SBI Life: SBI Life Insurance, which recently completed its initial share sale offer, will make its stock market debut on Tuesday. Its Rs 8,400 crore IPO, which was sold between September 20 and 22, was subscribed 3.58 times

Reliance Infrastructure: Greenko, backed by Singapore's GIC and Abu Dhabi Investment Authority, has sought to acquire Anil Ambani-led Reliance Infrastructure's flagship Mumbai electricity business for an enterprise value of Rs 13,000-14,000 crore (\$2.15 billion), said people aware of the matter.

- Auto stocks: Shares of auto companies are likely to stay in focus as automakers report their monthly sales numbers for September. Maruti Suzuki India has posted a growth of 9.3 per cent in its sales in September. Bajaj Auto has reported 14 per cent jump in monhtly sales.
- **Power Grid:** Power Grid: State-run Power Grid Corp said it has entered into a term loan facility agreement with ICICI Bank for Rs 3,270 crore.
- Tata Global Beverages: Starbucks, the world's largest coffee retailer, posted its slowest sales growth in India last year, likely indicating that its novelty factor is waning as it focuses on profitability and halts aggressive expansion. Tata Starbucks, the unit in India formed in partnership with the Tata Group, clocked net sales of Rs 272 crore, a growth of 14 per cent, during the year ended March 2017 and narrowed losses to Rs 32 crore.
- Lupin: The drugmaker has received final approval for its Doxycycline Hyclate Tablets USP, 75 mg and 150 mg from the USFDA to market a generic version of Aqua Pharmaceuticals, LLC's Acticlate Tablets, 75 mg and 150 mg.
- **S H Kelkar and Company:** The company has announced that Keva Fragrances, subsidiary of the Company has executed Share Purchase Agreement for acquisition of 100% share capital of VN Creative Chemicals on 29 September 2017.

Comments- Benchmark indices pared gains to end flat, losing over 1.5% in the week on foreign fund outflows amid worries that the government may widen its fiscal deficit target of 3.2% of gross domestic product for the year ending in March 2018 to boost an economy that grew at a slower pace than expected.

Ν	I	L	



3rd October,2017

Wallfort Research is also available on Bloomberg <Code WFSR>

Disclaimer: This document has been prepared by the Research Division of Wallfort Financial Services Ltd. Mumbai, India (WFSL) and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of WFSL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, WFSL has not independently verified the accuracy or completeness of the same. Neither WFSL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either WFSL or its affiliates or its directors or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. We may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

Disclosure: Wallfort Financial Services Ltd. / its affiliates entities / employees may hold a position in the stock(s) recommended above.